M&A Deal Summary

Amicus Therapeutics Acquires Celenex

On September 20, 2018, Amicus Therapeutics acquired life science company Celenex for 175M USD

Acquisition Highlights
  • This is Amicus Therapeutics’ 2nd transaction in the Life Science sector.
  • This is Amicus Therapeutics’ 2nd largest (disclosed) transaction.
  • This is Amicus Therapeutics’ 2nd transaction in the United States.
  • This is Amicus Therapeutics’ 1st transaction in Ohio.

M&A Deal Summary
Date 2018-09-20
Target Celenex
Sector Life Science
Buyer(s) Amicus Therapeutics
Deal Type Add-on Acquisition
Deal Value 175M USD
Advisor(s) RBC Capital Markets (Financial)
Fenwick & West (Legal)

Target

Celenex

Columbus, Ohio, United States
Celenex is a clinical stage gene therapy company. The lead programs in CLN6, CLN3, and CLN8 Batten disease are potential first-to-market curative therapies for these rare, devastating diseases. Celenex is based in Columbus, Ohio.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Amicus Therapeutics

Princeton, New Jersey, United States
Category Company
Founded 2002
Sector Life Science
Employees517
Revenue 399M USD (2023)
DESCRIPTION

Amicus Therapeutics is a biotechnology company at the forefront of therapies for rare and orphan diseases. Amicus Therapeutics was founded in 2002 and is based in Princeton, New Jersey.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 2 of 2
State (Ohio) 1 of 1
Country (United States) 2 of 2
Year (2018) 1 of 1
Size (of disclosed) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-09-30 Scioderm

Raleigh, North Carolina, United States

Scioderm, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies to address diseases with high unmet need, including rare diseases.

Buy $229M
Mergr

Product

Company

Legal